A physiologically connected multi-organ microfluidic platform that recreates the human gut-liver axis for studying oral drug absorption, first-pass metabolism, toxicity, inflammation, and inter-organ crosstalk.
- Overview
- Platform
- Advantages
- FAQs
Overview
The intestine and liver form one of the most important functional organ axes in the human body. Following oral administration, compounds are absorbed through the intestinal epithelium, transported through the portal circulation, and subsequently metabolized by the liver. This coordinated process strongly influences drug bioavailability, therapeutic efficacy, metabolite formation, and systemic toxicity.
Traditional in vitro models usually evaluate the intestine and liver separately, which limits their ability to reproduce organ-organ communication, dynamic transport, and first-pass metabolism. Animal models, while useful, often fail to predict human-specific absorption, metabolism, immune response, and toxicity due to species differences.
Intestine-Liver-on-a-chip is an advanced multi-organ microphysiological system designed to recreate the dynamic gut-liver axis under controlled microfluidic conditions. By integrating intestinal epithelial cells and liver cells in a connected platform, this system enables researchers to evaluate compound absorption, intestinal barrier function, hepatic metabolism, and downstream liver responses in a single physiologically relevant model.
What Is Intestine-Liver-on-a-chip?
Intestine-Liver-on-a-chip is a microengineered multi-organ platform that links an intestinal compartment with a hepatic compartment through controlled fluid flow. The system is designed to mimic key features of the human intestine-liver axis, including:
- Compartmentalized intestinal and hepatic culture chambers
- Microfluidic circulation that simulates inter-organ molecular transport
- Polarized intestinal epithelial barrier with apical and basolateral interfaces
- Functional liver compartment capable of metabolic and detoxification activities
- Dynamic communication between the gut and liver through soluble factors, metabolites, cytokines, and drug-derived products
Compared with static monoculture systems, the multi-organ chip allows researchers to study how the intestine and liver influence each other in real time. This is particularly valuable for oral drug development, food safety evaluation, microbiome-related research, inflammatory disease modeling, and toxicity assessment.
Fig. 1. Design of the integrated-gut-liver-on-a-chip (iGLC) platform to recapitulate NAFLD
(Yang J, Hirai Y, et al., 2023).
Our Intestine-Liver-on-a-chip Platform
Our Intestine-Liver-on-a-chip platform integrates human intestinal and hepatic models in a connected microfluidic device, enabling dynamic transport, first-pass metabolism analysis, and gut-liver crosstalk studies under controlled conditions.
Key Features
- Multi-organ integration: Connects intestinal and liver compartments in one chip.
- Dynamic microfluidic flow: Supports controlled exchange of drugs, metabolites, nutrients, and signaling molecules.
- Physiological intestinal barrier: Enables permeability, absorption, and epithelial barrier studies.
- Functional hepatic compartment: Supports metabolism, detoxification, and hepatotoxicity assessment.
- First-pass metabolism modeling: Recreates intestinal absorption followed by liver processing.
System Design & Validation
Our Intestine-Liver-on-a-chip system is engineered with compartmentalized microfluidic architecture to maintain tissue-specific culture environments while enabling controlled gut-to-liver communication. The platform is validated through structural, functional, and analytical assays to ensure reliable multi-organ performance.
- Intestinal module: Evaluated for epithelial morphology, tight junction formation, and barrier integrity.
- Liver module: Assessed for hepatic marker expression, albumin secretion, urea production, and CYP activity.
- Flow connection: Controlled microfluidic circulation enables defined inter-compartment communication.
- Analytical compatibility: Suitable for imaging, ELISA, qPCR, LC-MS/MS, cytokine assays, and toxicity biomarker detection.
- Quality control: Includes chip integrity, sterility, cell viability, and flow stability checks.
Applications
Our Intestine-Liver-on-a-chip platform supports a wide range of gut-liver axis and compound evaluation studies:
- Oral drug absorption: Evaluate intestinal permeability, transport, and bioavailability-related responses.
- First-pass metabolism: Study parent drug conversion and metabolite formation after intestinal exposure.
- Drug-induced liver injury: Assess hepatic toxicity following physiologically relevant intestinal absorption.
- Gut-liver disease modeling: Model NAFLD/NASH, inflammatory responses, and barrier dysfunction-associated liver injury.
- Microbiome-related research: Investigate the hepatic effects of intestinal or microbial metabolites.
- Food and chemical safety: Assess absorption, metabolism, and toxicity of dietary, nutraceutical, and environmental compounds.
Why Choose Our Intestine-Liver-on-a-chip
- Connected multi-organ model for direct analysis of gut-liver communication.
- Improved physiological relevance for oral absorption and first-pass metabolism studies.
- Dynamic microfluidic environment that better reflects inter-organ transport than static cultures.
- Flexible configuration with primary cells, iPSC-derived cells, organoid-derived cells, or disease-specific models.
- Customizable endpoints for permeability, metabolism, toxicity, inflammation, and disease modeling.
FAQs
Q: What makes Intestine-Liver-on-a-chip different from separate intestine and liver culture models?
The key advantage is multi-organ connectivity. In this platform, compounds or signaling molecules can pass from the intestinal compartment to the liver compartment through controlled microfluidic flow, enabling researchers to study absorption, metabolism, toxicity, and inter-organ communication in a single integrated system.
Q: Can this platform be used to study oral drug first-pass metabolism?
Yes. The chip is particularly suitable for modeling oral drug exposure. Test compounds can be applied to the intestinal side, transported across the intestinal barrier, and then delivered to the liver compartment for metabolic processing, allowing evaluation of both parent compounds and metabolites.
Q: What cell types can be incorporated into the chip?
The platform can be configured with intestinal epithelial cell lines, primary intestinal cells, iPSC-derived intestinal cells, intestinal organoid-derived cells, hepatocytes, hepatic stellate cells, Kupffer-like cells, liver organoids, or iPSC-derived hepatic cells depending on the research objective.
Q: Is the system suitable for inflammation or disease modeling?
Yes. The platform can be adapted to model intestinal barrier disruption, inflammatory cytokine exposure, metabolic stress, NAFLD/NASH-related responses, and other gut-liver axis-associated disease mechanisms. Co-culture with immune or stromal cells may also be incorporated for customized studies.
Q: What endpoints can be measured using this chip?
Common endpoints include intestinal permeability, TEER or barrier integrity, drug transport, metabolite formation, albumin secretion, urea production, CYP activity, cell viability, inflammatory cytokines, gene expression, immunostaining, and toxicity biomarkers such as ALT, AST, or LDH.
Advance your gut-liver axis research with a connected, dynamic, and human-relevant multi-organ chip platform.
Contact us today to discuss Intestine-Liver-on-a-chip configurations, assay design, validation options, and customized study solutions.
Online Inquiry